- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Palvella Therapeutics is seeking FDA approval for therapies developed using SELVA and Toiva trials.
3 reports, 1 independent
Updated Aug 4
Gone quiet
- Reports
- 3
- Developments
- 3
- Repetition
- 33%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Palvella Therapeutics is seeking FDA approval for therapies developed using SELVA and Toiva trials.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- SELVA is a clinical trial for QTORIN™ rapamycin.Sub-event
Palvella Therapeutics seeks FDA approval for therapies based on SELVA and Toiva trials.1 source
- QTORIN™ received positive designations from the FDA regarding its Phase 3 trial.
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
Coverage
Newest first; wire copies grouped- GlobeNewswirePalvella Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Phase 3 SELVA trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for microcyst
- Unknown outlet